A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies

[1]  T. Madden,et al.  Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Myers,et al.  Role of high-dose chemotherapy and autologous stem cell support in treatment of breast cancer. , 1993, Hematology/oncology clinics of North America.

[3]  G. Rosner,et al.  High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Rosner,et al.  Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. , 1993, Blood.

[5]  B. Teicher,et al.  A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Bast,et al.  Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer , 1991, International Journal of Cancer.

[7]  P. Engstrom,et al.  Phase I/pharmacokinetic reevaluation of thioTEPA. , 1991, Cancer research.

[8]  Peters Wp.  High-dose chemotherapy and autologous bone marrow support for breast cancer. , 1991, Important advances in oncology.

[9]  W. Peters.  High-dose chemotherapy and autologous bone marrow support for breast cancer. , 1991, Important advances in oncology.

[10]  J. White,et al.  Platelets acquire a secretion defect after high‐dose chemotherapy , 1990, Cancer.

[11]  D. Waxman,et al.  Biotransformation of N,N',N''-triethylenethiophosphoramide: oxidative desulfuration to yield N,N',N''-triethylenephosphoramide associated with suicide inactivation of a phenobarbital-inducible hepatic P-450 monooxygenase. , 1990, Cancer research.

[12]  P. O'dwyer,et al.  High-performance liquid chromatographic analysis of N,N',N"-triethylenethiophosphoramide in human plasma. , 1989, Journal of chromatography.

[13]  R. Bast,et al.  High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Ratain,et al.  Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  C. Begg,et al.  Pharmacokinetics of continuous-infusion high-dose thiotepa. , 1987, Cancer treatment reports.

[16]  J. Fay,et al.  Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Bast,et al.  High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Fay,et al.  Treatment of metastatic malignant melanoma with intensive melphalan and autologous bone marrow transplantation. , 1985, Cancer treatment reports.

[19]  W. Haseltine,et al.  Alkylating agent resistance: in vitro studies with human cell lines. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Egorin,et al.  Gas-liquid chromatographic analysis of N,N',N''-triethylene thiophosphoramide and N,N',N''-triethylene phosphoramide in biological samples. , 1985, Journal of chromatography.

[21]  F. Schabel,et al.  Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology , 1984, Pharmacology & therapeutics.

[22]  H. Skipper,et al.  Establishment of cross-resistance profiles for new agents. , 1983, Cancer treatment reports.

[23]  Schabel Fm.  Fundamentals in cancer chemotherapy: introduction. , 1978 .